Abstract
CARD14/CARMA2 is a scaffold molecule whose genetic alterations are linked to human inherited inflammatory skin disorders. However, the mechanisms through which CARD14/CARMA2 controls innate immune response and chronic inflammation are not well understood. By means of a yeast two-hybrid screening, we identified the UBA Domain Containing 1 (UBAC1), the non-catalytic subunit of the E3 ubiquitin-protein ligase KPC complex, as an interactor of CARMA2sh, the CARD14/CARMA2 isoform mainly expressed in human keratinocytes. UBAC1 participates in the CARMA2sh/TANK complex and promotes K63-linked ubiquitination of TANK. In human keratinocytes, UBAC1 negatively regulates the NF-κF-activating capacity of CARMA2sh following exposure to poly (I:C), an agonist of Toll-like Receptor 3. Overall, our data indicate that UBAC1 participates in the inflammatory signal transduction pathways involving CARMA2sh.
Keywords: CARD14, CARMA2sh, UBAC1, NF-κB, psoriasis, TANK, Ubiquitin, BCL10
1. Introduction
In human keratinocytes, the scaffold protein CARD14/CARMA2sh (CARMA2sh) controls signal transduction pathways converging on the activation of the transcription factor NF-κB, which, in turn, regulates the expression of inducible genes involved in inflammatory, proliferative and cellular stress responses [1,2]. As a consequence of resulting dis-regulated NF-κB activity, mutations in CARMA2 have been shown to be causative of several inflammatory disorders of the human skin, including familial psoriasis [2,3,4,5,6,7]. The NF-κB-inducing capacity of CARMA2sh relies in the assembly of a molecular complex that, in addition to CARMA2sh, requires the adapter molecule BCL10 and the protease MALT1 (CBM complex) [8,9]. Organization of the CBM complex by CARMA proteins occurs through the formation of higher order structures consisting of branched BCL10 filaments sheathed with MALT1 [10,11]. BCL10 filaments allow MALT1 oligomerization and activation, which eventually ensues in recruitment of the IKK complex and NF-κB activation [1,2,3,4,12]. In addition to the component of the CBM complex, and similarly to other CARMA proteins, CARMA2sh function is modulated by a number of CARMA2sh-interacting proteins [13,14,15] and by the de-ubiquitinase A20 [8]. We have also recently shown that CARMA2sh and the adapter protein TANK are required to activate the NF-κB response following exposure to poly (I:C), an agonist of Toll-like Receptor 3 [16]. Specifically, these data indicated that the complex CARMA2sh/TANK regulates the balance between inflammatory and antiviral responses in keratinocytes [16], a regulatory function shared also by the similar protein CARMA3 [17,18].
Studying molecules capable of modulating the function of CARMA2sh is particularly important, as it helps our understanding of the regulation of inflammatory mechanisms in human keratinocytes and they represent potential therapeutic targets for the treatment of inflammatory skin diseases [19].
Here we find that the UBA Domain Containing 1 (UBAC1), the non-catalytic subunit of the E3 ubiquitin-protein ligase KPC complex [20,21], binds to the CARMA2sh/TANK complex and modulates its NF-κB-inducing activity by modifying the ubiquitination state of TANK.
2. Results and Discussion
In order to identify novel interactors of CARMA2sh, we performed a panel of yeast two-hybrid assay screenings using as bait CARMA2sh fused to the DNA binding domain of transcription factor GAL4. A plasmid library of fusion between the transcription activation domain of GAL4 and cDNAs from human peripheral blood leucocytes was screened for interaction with GAL4-CARMA2sh in the yeast reporter strain AH109. Several clones that activated the β-galactosidase reporter gene were isolated. Sequence analysis revealed that several isolated plasmids, identified recurrently in multiple independent copies, encoded for the region encompassing amino acids 99-404 of UBAC1/KPC2 (UBAC1), the non-catalytic subunit of the E3 ubiquitin-protein ligase KPC complex [20,21]. Interaction of UBAC1 with CARMA2sh was confirmed by individual plasmid transformations in the yeast reporter strain AH109 (Table 1).
Table 1.
Protein Fused to GAL4 Domain | Yeast Growth on Selective Media | |
---|---|---|
DNA-Binding | Activating | |
- | UBAC1 | - |
Vector | UBAC1 | - |
FADD | UBAC1 | - |
CARMA2sh | UBAC1 | +++ |
CARMA2sh | - | - |
To verify whether this interaction also occurs in mammalian cells, HEK293T cells were co-transfected with plasmids expressing FLAG-tagged UBAC1 together with a vector encoding for HA-tagged CARMA2sh. Cell lysates were immunoprecipitated with anti-FLAG-coated beads and the presence of coprecipitating CARMA2sh was assessed by immunoblot experiments probed with anti-HA antibody. The results shown in Figure 1A indicate that CARMA2sh coprecipitates with UBAC1 in co-transfection experiments. We further confirmed interaction of UBAC1 with endogenous CARMA2sh through a pull-down assay (Figure 1B). For this, lysates from HaCaT cells were incubated with recombinant GST or recombinant GST-UBAC1 fusion protein. CARMA2sh pull-down from HaCaT lysates was detectable using GST-UBAC1 but not GST alone, indicating that UBAC1 directly binds CARMA2sh in vitro. Given the modular architecture of CARMA2sh, we sought to determine which domain of CARMA2sh is involved in interaction with UBAC1. For this, CARMA2sh deletion mutants where co-transfected with UBAC1 and tested for interaction. As shown in Figure 1C, the polypeptides encoding for the coiled coil (CARMA2CCL, corresponding to CARMA2sh123–550) or the PDZ domain (CARMA2PDZ, corresponding to CARMA2sh550–690) of CARMA2sh are both able to associate with UBAC1, whereas the CARD domain (CARMA2CARD, corresponding to CARMA2sh1–123) did not. The psoriasis-linked CARMA2sh mutants, CARMA2shE138A and CARMA2shE142G, and the alternatively spliced isoform CARMA2cl [8] also bind to UBAC1 (Figure 1D).
We have previously shown that in human keratinocytes CARMA2sh plays a key role in the signal transduction pathway that connects TLR3 and other pathogen-associated molecular patterns (PAMPs) recognition to NF-κB activation. Thus, in order to gain insights into the biological significance of UBAC1 in the signal transduction pathways involving CARMA2sh, Normal Human Epidermal Keratinocytes (NHEK) were infected with a retroviral vector encoding for UBAC1 or GFP, and the expression level of target genes such as antimicrobic peptides (S100A8, S100A9, S100A12), inflammatory cytokines (IL1, IL6, IL8, CCL20) and the IRF3-responsive anti-viral cytokine IFN-β was analyzed after exposure for 24 h to the TLR3 agonist Poly-inosinic-cytidylic acid [poly (I:C)]. Real time-PCR analysis indicates that expression of UBAC1 significantly impairs induction of TLR3 downstream target genes, acting on both NF-κB and IRF3 signaling (Figure 2A). Conversely, abrogation of UBAC1 expression in NHEK using short hairpin RNAs targeting human UBAC1 exacerbates NHEK response to TLR3 engagement (Figure 2B).
Since UBAC1 is involved in ubiquitination pathways, we verified whether UBAC1 expression modifies the ubiquitination state of CARMA2sh or TANK. For this, HEK293T cells were co-transfected with CARMA2sh or TANK in combination with UBAC1, and the ubiquitination state of these proteins was monitored by immunoblot experiments. As shown in Figure 3A, UBAC1 associates with TANK and significantly increases its ubiquitination. Because ubiquitin possesses seven lysines, and ubiquitin moieties can be conjugated through one of their lysine residues (K6, K11, K27, K29, K33, K48 and K63) or the N-terminal methionine residue (M1) [22], we used ubiquitin mutants possessing single lysine residues to investigate the nature of UBAC1-promoted polyubiquitination of TANK.
These experiments, shown in Figure 3B, indicate that UBAC1 mostly promotes K63- and K-29-linked ubiquitination of TANK. Notably, K63- and K-29-linked ubiquitinated forms of TANK coprecipitate with UBAC1.
Because viability and proliferation of keratinocytes are critically regulated to maintain skin homeostasis [23], we performed an MTT assay on NHEK primary cells in which UBAC1 was ectopically expressed at seeding and 24, 48, and 72 h after. Interestingly, UBAC1 over-expression accelerates proliferation and cluster formation of NHEK cells observed at 48 and 72 h after seeding (Figure 4A). Conversely, UBAC1-silenced primary keratinocytes grow slower than controls, independently of confluence at seeding (Figure 4B).
Genetic variations in the CARMA2 gene are associated with familiar inflammatory skin diseases [1,2,3,4,5,6,7]. Recent studies performed using genetically modified murine strains expression CARMA2 variants associated to familiar psoriasis have shown that keratinocyte-specific expression of altered forms of CARMA2 is sufficient to trigger skin inflammation, mostly mediated by the cytokines IL-17A, IL-23 and TNFα [24,25,26,27]. However, the molecular mechanisms by which CARMA2sh controls inflammatory pathways are still poorly understood. We have previously shown that in human keratinocytes both the adapter protein TANK and CARMA2sh form a complex participating in a signal transduction pathway controlling the NF-κB response following exposure to poly I:C [16], a mimetic of double-stranded RNA and known to interact with TLR3 [28,29]. TANK has a broad role in regulating the antiviral and inflammatory immune response, promoting activation of the IRF3/IRF7 pathway as well as induction of NF-κB [30,31,32]. Here we show that UBAC1, the noncatalytic subunit of the E3 complex KPC contributes to the CARMA2sh/TANK complex and promotes K63-linked ubiquitination of TANK. UBAC1 was originally identified as a component of the E3 complex KPC, which includes the catalytic subunit KPC1 and KPC2/UBAC1 [20]. KPC interacts with and ubiquitinates p27 (Kip1), thereby promoting its degradation [20]. However, protein degradation by the proteosomal machinery is generally mediated by K48-linked ubiquitination of target proteins [33]. Our experiments show that UBAC1 also regulates K63-linked ubiquitination reactions by promoting K63-linked ubiquitination of TANK. Indeed, emerging evidence indicate that K63-linked ubiquitination plays a pivotal role in the regulation of pathways implicated in the inflammatory response [34,35]. Overall, our data indicate that UBAC1 participates to TLR3 signaling in keratinocytes, affecting also cell viability and proliferation. Moreover, the ubiquitination events involving UBAC1 and TANK should be considered within the molecular mechanisms that modulate the physiological function of CARMA2sh and of its psoriasis-linked mutants. Future work will further address this aspect.
3. Materials and Methods
The two-hybrid screening. The two-hybrid screening carried on using CARMA2sh as bait has been described in [13]. Briefly, yeast strain AH109 GAL4−/− was first transformed with pGBKT7 plasmid carrying a CARMA2sh cDNA bait fused with DBD of GAL4 using the lithium acetate/PEG 3000 procedure. Transformant colonies were selected by their ability to grow on a selective medium lacking tryptophan. Expression of bait GAL4DBD-CARMA2sh was assessed by western blot analysis. For library screening, yeast AH109 expressing GAL4DBD-CARMA2sh was transformed with a human peripheral blood leucocyte cDNA library cloned in pACT2 vector (Clontech, Mountain View, California, USA) in fusion with GAL4TAD. A total of 2 × 106 clones were screened for interaction with GAL4DBD-CARMA2sh using selective growth on minimal medium lacking nutrients whose biosynthesis is mediated by genes under control of GAL4 transcriptional activity.
Cell Culture and Tranfection. HEK293T and HaCaT cells were purchased from ATCC and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% FBS. Normal Human Epidermal Keratinocytes (NHEK) were purchased from Lonza and cultured according to the provided instructions. HEK293T were transfected using calcium phosphate precipitation; NHEK transfection was performed using DreamFect Gold Transfection Reagent (OZ Biosciences, Marseille, France) according to the manufacturer’s instruction. Retroviral infections were carried out as previously described [13].
GST pull-down. UBAC1-glutathione S-transferase (GST) fusion protein was produced in Escherichia coli DH5α-cells using pGEX-5x-1 as expression plasmid (GE Healthcare, Chicago, IL, USA). Transformed bacteria were grown at 37 °C until an A600 of 0.6 and induced with 1 mM isopropyl1-thio-β-D-galactopyranoside for 3 h at 37 °C. UBAC1-GST fusion protein expression was assessed by SDS-PAGE. Cells were collected in PBS and lysed with five freeze-thaw cycles followed by 1 min of sonication. After centrifugation, the soluble fraction was bound to glutathione-Sepharose beads (GE Healthcare, Chicago, IL, USA) overnight at 4 °C in an EconoPac chromatography column (Bio-Rad) on a rotating wheel. Beads were then washed three times with PBS and resuspended in Lysis Buffer with protease inhibitors (Roche Applied Science). Lysates obtained from HaCaT cells were mixed with Sepharose-bound GST-UBAC1 (1.5 μg) overnight at 4 °C on a rotating wheel. Beads were centrifugated, washed three times with lysis buffer without protease inhibitors, and resuspended in reducing Sample Buffer. Samples were boiled for 5 min, and supernatants were separated by SDS-PAGE followed by blotting and incubation with CARMA2 antibody.
Immunoblot analysis and coprecipitation. Cell lysates were made in lysis buffer (150 mM NaCl, 20 mM Hepes, pH 7.4, 1% Triton X-100, 10% glycerol) and a mixture of proteases inhibitors (Roche, Basel, Switzerland) according to the manufacturer’s instructions. Proteins were separated by SDS–PAGE, transferred onto nitrocellulose membrane, and incubated with primary antibodies followed by horseradish peroxidase-conjugated secondary antibodies (Amersham Biosciences, Little Chalfont, UK). Blots were developed using the ECL system (Amersham Biosciences, Little Chalfont, UK). For co-immunoprecipitation experiments, cells were lysed in lysis buffer and immunocomplexes were bound to protein A/G (Amersham Biosciences, Little Chalfont, UK) for 2 h at 4 °C. Immunocomplexes were extensively washed, resolved by SDS–PAGE, and analyzed by immunoblot assay. Sources of antisera and monoclonal antibodies were the following—anti-FLAG, anti-β-Actin, Sigma; anti-HA, anti-TANK anti-CARMA2, anti-ubiquitin (P4D1), Santa Cruz Biotechnology.
Real-time RT-PCR. Total RNA was isolated from cells using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). The reverse transcriptase reaction was performed using 1 μg of total RNA in a 20 μL reaction. A total of 10 ng of the resulting cDNA was used in the subsequent amplification step along with 300 nM of each primer. For the data analysis, the geometric mean values of β−actin and succinyl-CoA synthetase β-subunit fragment were used for the normalization. The ΔΔCt method was used for the relative transcription level calculation. Real-time PCR reactions were performed in triplicate by using the SYBR Green PCR Master Mix (Qiagen, Hilden, Germany) in a 7900HT system (Applied Biosystems, Foster City, CA, USA). shRNAs targeting UBAC1 were obtained from Sigma-Aldrich (St. Louis, MO, USA) and have the following sequence:
TRCN0000074948 (shRNA1)
CCGGGCTGTGGTAATTCTATTTGTACTCGAGTACAAATAGAATTACCACAGCTTTTTG
TRCN0000291039 (shRNA2)
CCGGCGGACTATTGTTCAGCTAGAACTCGAGTTCTAGCTGAACAATAGTCCGTTTTTG
For cell treatment, after attaining confluence, the culture medium of the NHEK cell monolayers was removed. Fresh medium with 20 μg/mL Poly (I:C) was added to cells for 24 h at 37 °C, 95% humidity and 5% CO2. At the end of incubation, cells were washed with cell culture medium and lysed with TRI Reagent (Sigma-Aldrich, St. Louis, MO, USA). Lysed cells were collected and stored at −80 °C until real-time time polymerase chain reaction (PCR) was performed.
MTT assay. At the end of each testing time, MTT solution (0.5 mg/mL) was added to each well, and the plates were incubated for 1 h at 37 °C. The MTT solution was removed, and isopropyl alcohol was added in order to dissolve formazan crystals. The absorbance at 570 nm was read on a microplate spectrophotometer (Applied Biosystem, Foster City, CA, USA) and background absorbance was subtracted to raw optical densities. Graphs are representative of three replicates and error bars are calculated as standard deviations.
Acknowledgments
We thank all the members of the lab for critical reading of the manuscript.
Supplementary Materials
Supplementary materials can be found at https://www.mdpi.com/1422-0067/21/24/9365/s1.
Author Contributions
P.M., M.C., I.S., I.P., S.V., G.T., L.Z. and R.S. conceived, designed and performed the experiments; R.S., T.Z. and P.V. analyzed the data; P.V. and T.Z. wrote the paper. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Conflicts of Interest
The authors declare no conflict of interest.
Footnotes
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Scudiero I., Vito P., Stilo R.N. The three CARMA sisters: So different, so similar: A portrait of the three CARMA proteins and their involvement in human disorders. J. Cell Physiol. 2014;229:990–997. doi: 10.1002/jcp.24543. [DOI] [PubMed] [Google Scholar]
- 2.Zotti T., Polvere I., Voccola S., Vito P., Stilo R. CARD14/CARMA2 Signaling and its Role in Inflammatory Skin Disorders. Front. Immunol. 2018;9:2167. doi: 10.3389/fimmu.2018.02167. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Mellett M. Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease. Cell Immunol. 2020;354:104147. doi: 10.1016/j.cellimm.2020.104147. [DOI] [PubMed] [Google Scholar]
- 4.Van Nuffel E., Schmitt A., Afonina I.S., Schulze-Osthoff K., Beyaert R., Hailfinger S. CARD14-Mediated Activation of Paracaspase MALT1 in Keratinocytes: Implications for Psoriasis. J. Investig. Dermatol. 2017;137:569–575. doi: 10.1016/j.jid.2016.09.031. [DOI] [PubMed] [Google Scholar]
- 5.Jordan C.T., Cao L., Roberson E.D., Pierson K.C., Yang C.F., Joyce C.E., Ryan C., Duan S., Helms C.A., Liu Y., et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 2012;90:784–795. doi: 10.1016/j.ajhg.2012.03.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Jordan C.T., Cao L., Roberson E.D., Duan S., Helms C.A., Nair R.P., Duffin K.C., Stuart P.E., Goldgar D., Hayashi G., et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am. J. Hum. Genet. 2012;90:796–808. doi: 10.1016/j.ajhg.2012.03.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Berki D.M., Liu L., Choon S.E., David Burden A., Griffiths C.E.M., Navarini A.A., Tan E.S., Irvine A.D., Ranki A., Ogo T., et al. Activating CARD14 Mutations Are Associated with Generalized Pustular Psoriasis but Rarely Account for Familial Recurrence in Psoriasis Vulgaris. J. Investig. Dermatol. 2015;135:2964–2970. doi: 10.1038/jid.2015.288. [DOI] [PubMed] [Google Scholar]
- 8.Scudiero I., Zotti T., Ferravante A., Vessichelli M., Vito P., Stilo R. Alternative splicing of CARMA2/CARD14 transcripts generates protein variants with differential effect on NF-κB activation and endoplasmic reticulum stress-induced cell death. J. Cell Physiol. 2011;226:3121–3131. doi: 10.1002/jcp.22667. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Afonina I.S., Van Nuffel E., Baudelet G., Driege Y., Kreike M., Staal J., Beyaert R. The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes. EMBO Rep. 2016;17:914–927. doi: 10.15252/embr.201642109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Guiet C., Vito P. Caspase recruitment domain (CARD)-dependent cytoplasmic filaments mediate bcl10-induced NF-kappaB activation. J. Cell Biol. 2000;148:1131–1140. doi: 10.1083/jcb.148.6.1131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Qiao Q., Yang C., Zheng C., Fontan L., David L., Yu X., Bracken C., Rosen M., Melnick A., Egelman E.H., et al. Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: Nucleation-induced filamentous assembly. Mol. Cell. 2013;51:766–779. doi: 10.1016/j.molcel.2013.08.032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Stilo R., Liguoro D., Di Jeso B., Formisano S., Consiglio E., Leonardi A., Vito P. Physical and functional interaction of CARMA1 and CARMA3 with Ikappa kinase gamma-NFkappaB essential modulator. J. Biol. Chem. 2004;279:34323–34331. doi: 10.1074/jbc.M402244200. [DOI] [PubMed] [Google Scholar]
- 13.D’Andrea E.L., Ferravante A., Scudiero I., Zotti T., Reale C., Pizzulo M., De La Motte L.R., De Maio C., Mazzone P., Telesio G., et al. The Dishevelled, EGL-10 and pleckstrin (DEP) domain-containing protein DEPDC7 binds to CARMA2 and CARMA3 proteins and regulates NF-κB activation. PLoS ONE. 2014;9:e116062. doi: 10.1371/journal.pone.0116062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Telesio G., Scudiero I., Pizzulo M., Mazzone P., Zotti T., Voccola S., Polvere I., Vito P., Stilo R. The E3 Ubiquitin Ligase RNF7 Negatively Regulates CARD14/CARMA2sh Signaling. Int. J. Mol. Sci. 2017;18:2581. doi: 10.3390/ijms18122581. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Scudiero I., Mazzone P., D’Andrea L.E., Ferravante A., Zotti T., Telesio G., De Rubis G., Reale C., Pizzulo M., Muralitharan S., et al. CARMA2sh and ULK2 control pathogen-associated molecular patterns recognition in human keratinocytes: Psoriasis-linked CARMA2sh mutants escape ULK2 censorship. Cell Death Dis. 2017;8:e2627. doi: 10.1038/cddis.2017.51. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Voccola S., Polvere I., Madera J.R., Paolucci M., Varricchio E., Telesio G., Porcaro P., Vito P., Stilo R., Zotti T. CARD14/CARMA2sh and TANK differentially regulate poly(I:C)-induced inflammatory reaction in keratinocytes. J. Cell Physiol. 2020;235:1895–1902. doi: 10.1002/jcp.29161. [DOI] [PubMed] [Google Scholar]
- 17.Jiang C., Zhou Z., Quan Y., Zhang S., Wang T., Zhao X., Morrison C., Heise M.T., He W., Miller M.S., et al. CARMA3 Is a Host Factor Regulating the Balance of Inflammatory and Antiviral Responses against Viral Infection. Cell Rep. 2016;14:2389–2401. doi: 10.1016/j.celrep.2016.02.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Causton B., Pardo-Saganta A., Gillis J., Discipio K., Kooistra T., Rajagopal J., Xavier R.J., Cho J.L., Medoff B.D. CARMA3 Mediates Allergic Lung Inflammation in Response to Alternaria alternata. Am. J. Respir. Cell Mol. Biol. 2018;59:684–694. doi: 10.1165/rcmb.2017-0181OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Van Nuffel E., Staal J., Baudelet G., Haegman M., Driege Y., Hochepied T., Afonina I.S., Beyaert R. MALT1 targeting suppresses CARD14-induced psoriatic dermatitis in mice. EMBO Rep. 2020;21:e49237. doi: 10.15252/embr.201949237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Kamura T., Hara T., Matsumoto M., Ishida N., Okumura F., Hatakeyama S., Yoshida M., Nakayama K., Nakayama K.I. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at G1 phase. Nat. Cell Biol. 2004;6:1229–1235. doi: 10.1038/ncb1194. [DOI] [PubMed] [Google Scholar]
- 21.Kotoshiba S., Kamura T., Hara T., Ishida N., Nakayama K.I. Molecular dissection of the interaction between p27 and Kip1 ubiquitylation-promoting complex, the ubiquitin ligase that regulates proteolysis of p27 in G1 phase. J. Biol. Chem. 2005;280:17694–17700. doi: 10.1074/jbc.M500866200. [DOI] [PubMed] [Google Scholar]
- 22.Masato A., Dikic I., Bremm A. Ubiquitin chain diversity at a glance. J. Cell Sci. 2016;129:875–880. doi: 10.1242/jcs.183954. [DOI] [PubMed] [Google Scholar]
- 23.Blanpain C., Fuchs E. Epidermal homeostasis: A balancing act of stem cells in the skin. Nat. Rev. Mol. Cell Biol. 2009;10:207–217. doi: 10.1038/nrm2636. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Manils J., Webb L.V., Howes A., Janzen J., Boeing S., Bowcock A.M., Ley S.C. CARD14(E138A) signalling in keratinocytes induces TNF-dependent skin and systemic inflammation. eLife. 2020;9:e56720. doi: 10.7554/eLife.56720. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Wang M., Zhang S., Zheng G., Huang J., Songyang Z., Zhao X., Lin X. Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A. Immunity. 2018;49:66–79. doi: 10.1016/j.immuni.2018.05.012. [DOI] [PubMed] [Google Scholar]
- 26.Mellett M., Meier B., Mohanan D., Schairer R., Cheng P., Satoh T.K., Kiefer B., Ospelt C., Nobbe S., Thome M., et al. CARD14 Gain-of-Function Mutation Alone Is Sufficient to Drive IL-23/IL-17-Mediated Psoriasiform Skin Inflammation In Vivo. J. Investig. Dermatol. 2018;138:2010–2023. doi: 10.1016/j.jid.2018.03.1525. [DOI] [PubMed] [Google Scholar]
- 27.Sundberg J.P., Pratt C.H., Silva K.A., Kennedy V.E., Qin W., Stearns T.M., Frost J., Sundberg B.A., Bowcock A.M. Gain of function p.E138A alteration in Card14 leads to psoriasiform skin inflammation and implicates genetic modifiers in disease severity. Exp. Mol. Pathol. 2019;110:104286. doi: 10.1016/j.yexmp.2019.104286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Marshall-Clarke S., Downes J.E., Haga I.R., Bowie A.G., Borrow P., Pennock J.L., Grencis R.K., Rothwell P. Polyinosinic acid is a ligand for toll-like receptor 3. J. Biol. Chem. 2007;282:24759–24766. doi: 10.1074/jbc.M700188200. [DOI] [PubMed] [Google Scholar]
- 29.Matsumoto M., Seya T. TLR3: Interferon induction by double-stranded RNA including poly(I:C) Adv. Drug Deliver. Rev. 2008;60:805–812. doi: 10.1016/j.addr.2007.11.005. [DOI] [PubMed] [Google Scholar]
- 30.Sharma S., tenOever B.R., Grandvaux N., Zhou G.P., Lin R., Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science. 2003;300:1148–1151. doi: 10.1126/science.1081315. [DOI] [PubMed] [Google Scholar]
- 31.Häcker H., Redecke V., Blagoev B., Kratchmarova I., Hsu L.-C., Wang G.G., Kamps M.P., Raz E., Wagner H., Häcker G., et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature. 2006;439:204–207. doi: 10.1038/nature04369. [DOI] [PubMed] [Google Scholar]
- 32.Chariot A., Leonardi A., Muller J., Bonif M., Brown K., Siebenlist U. Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases. J. Biol. Chem. 2002;277:37029–37036. doi: 10.1074/jbc.M205069200. [DOI] [PubMed] [Google Scholar]
- 33.Komander D., Rape M. The ubiquitin code. Annu. Rev. Biochem. 2012;81:203–229. doi: 10.1146/annurev-biochem-060310-170328. [DOI] [PubMed] [Google Scholar]
- 34.Wang G., Gao Y., Li L., Jin G., Cai Z., Chao J.I., Lin H.K. K63-linked ubiquitination in kinase activation and cancer. Front. Oncol. 2012;2:5. doi: 10.3389/fonc.2012.00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Skaug B., Jiang X., Chen Z.J. The role of ubiquitin in NF-kappaB regulatory pathways. Annu. Rev. Biochem. 2009;78:769–796. doi: 10.1146/annurev.biochem.78.070907.102750. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.